APA (7th ed.) Citation

Araujo L, Kyatham S, Bzdek KG, Higuchi K, & Greene N. (2023). Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. Dove Medical Press.

Chicago Style (17th ed.) Citation

Araujo L, Kyatham S, Bzdek KG, Higuchi K, and Greene N. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. Dove Medical Press, 2023.

MLA (9th ed.) Citation

Araujo L, et al. Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States. Dove Medical Press, 2023.